PHASE
HOLOGRAPHIC
IMAGING

ANNUAL GENERAL MEETING

October 27, 2023

CONNECTING THE DOTS



Direct right issue

Convertible loan

Distribution agreement Altium

RIGHT ISSUE, WHY NOT?

- Right issue: heavy discount and dilution
- Risk of down spiral on the share price
- Financial cost presently between 15-21% of the issue

→ Could jeopardize TO4

DIRECT ISSUE

- Reduce dilution and financial costs
- Combination of the direct issue and acquiring Convertibles optimal solution
- Show commitments from Altium

DISTRIBUTION CONTRACT

- PHI is not a global sales organization
- PHI needs to focus on project development and GMP
- The regenerative initiative will demand total focus for PHI from a marketing/ advocating for QPI technology point of view

REGENERATIVE MEDICINE

What can we do, and who do we need to partner with?



CELL SAMPLING

- Potential customers: all regional hospitals and specialized clinics
- The QC journey with the patient journal starts at this point
- AI can most likely answer: Is the sample good enough?
- PHI's strategy to use standard equipment in hardware makes our system cost-effective compared with competitors.



This requires an easy-to-use QPI-based cell analyzer and a unique container for sampling and transport.

POINT OF CARE

- Potential customers: regional hospitals and specialized clinics
- Collecting QC data for the patient journal
- Most likely very standardized, cost-efficient system needs

This requires an easy-to-use, high-precision QPI-based cell analyzer, as well as cell culture vessels optimized for growth and modification.

TRANSPORT

- Potential customers: transport companies
- The cells need to be transported live and not, as before, frozen
- Collecting QC data for the patient journal

This requires an easy-to-use QPI-based cell analyzer and a unique container for sampling and transport.

LARGE SCALE MANUFACTURING

- Potential customer: big pharma
- Collecting QC data for the patient journal
- AI for prognosis and resource optimization



This requires highly automated QPI-based cell analyzers that are tailored to each facility and to each part of the process.

BED SIDE

- Potential customers: regional hospitals and specialized clinics
- Collecting QC data for the patient journal



Here, a data-driven decision-making tool is needed that supports healthcare professionals in a final approval of the cell sample before injection, based on information from QPI, among other things.

DATA COLLECTION

All production steps generate large amounts of data, including images, temperature measurements, gas composition information, process and handling data, patient data, etc.

Collecting and compiling all relevant data in the cloud makes it available for immediate analysis, allowing for immediate feedback.

Deviations in the manufacturing process can be analyzed instantly and lead to fine-tuning that optimizes cell health, growth, potency and quality.

PATIENT JOURNALS

Since regenerative medicine carries the promise of being able to cure today’s incurable diseases, for regulatory reasons, but also for health reasons for the patient, all data will need to be stored securely, at least for the patient's lifetime.

THANK YOU